Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease

Sezen, Duygu; Verma, Vivek; He, Kewen; Abana, Chike; Barsoumian, Hampartsaum; Ning, Matthew; Tang, Chad; HÜRMÜZ, PERVİN; Puebla-Osorio, Nahum; Chen, Dawei; Tendler, Irwin; Comeaux, Nathan; Quynh-Nhu Nguyen, Quynh-Nhu; Chang, Joe; Welsh, James

doi:10.1016/j.semradonc.2021.02.005

Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease

Atıf İçin Kopyala

Sezen D., Verma V., He K., Abana C. O., Barsoumian H., Ning M. S., ...Daha Fazla

SEMINARS IN RADIATION ONCOLOGY, cilt.31, sa.3, ss.217-226, 2021 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 31 Sayı: 3
Basım Tarihi: 2021
Doi Numarası: 10.1016/j.semradonc.2021.02.005
Dergi Adı: SEMINARS IN RADIATION ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
Sayfa Sayıları: ss.217-226
Hacettepe Üniversitesi Adresli: Evet

Özet

Metastatic cancer is inherently heterogeneous, and patients with metastatic disease can experience vastly different oncologic outcomes depending on several patient-and disease specific characteristics. Designing trials for such a diverse population is challenging yet necessary to improve treatment outcomes for metastatic-previously thought to be incurable-disease. Here we review core considerations for designing and conducting clinical trials involving radiation therapy and immunotherapy for patients with metastatic cancer. Semin Radiat Oncol 31:217-226 Published by Elsevier Inc.